Hello,
This is the KIMES Secretariat.

From March 14 (Thursday) to March 17 (Sunday), KIMES 2024 was successfully held at COEX, Seoul, 

thanks to your enthusiastic support. During the four-day event, 1,350 companies participated, 

and we had 70,760 visitors, making it a resounding success.

With such a large number of participants, there was a variety of medical device products showcased. 

Let’s take a closer look at which companies exhibited and which medical devices were featured through on-site interviews!

ReadyCure, a Customized Dementia Treatment System Utilizing Low-Dose Radiation

ReadyCure is a platform company providing the “Digital X-ray-Based Dementia Treatment System 

for Brain Immune Function Recovery (product name: HeLaXON)." Based on initial exploratory clinical 

research on the therapeutic effects of low-dose radiation, ReadyCure is developing a medical device for 

dementia treatment. This device leverages low-dose radiation therapy and high-powered carbon nanotubes, 

making it more economical and effective compared to conventional filament-based X-ray devices.

Q. Could you briefly introduce ReadyCure?

ReadyCure develops medical equipment for treating Alzheimer’s dementia using digital X-rays. 

This device aims to restore the function of microglia, immune cells within the brain, to aid in dementia treatment.

Q. Could you explain in detail the mechanism of HeLaXON 1X?

HeLaXON 1X delivers optimal radiation to patients using a digital X-ray source based on carbon nanotubes. 

This radiation restores the function of microglial cells in the brain, thereby helping to maintain 

or improve cognitive function. Specifically, it allows precise and efficient treatment by 

embedding multiple digital X-ray sources within a fixed gantry.

Q. What are the effects and advantages of HeLaXON 1X?

HeLaXON 1X has shown efficacy in maintaining or improving cognitive function 

in approximately 80% of dementia patients, boasting a much higher success rate 

than traditional treatments. Additionally, the treatment is relatively simple and 

has minimal side effects, making it a safe option for patients.

Q. Could you share your future plans?

We are finalizing prototype production and, barring any significant issues, 

HeLaXON 1X will be available in general hospitals within three years. 

We also plan to expand into markets outside Korea, including the U.S. and Europe, 

for which we are pursuing FDA approval. Our goal is to achieve global success.

"ReadyCure, Introducing the Dementia Treatment System at KIMES 2024!"

HeLaXON 1X stands out as a fundamental treatment that improves cognitive function 

by restoring the function of microglial cells, astrocytes, and other key immune cells in the brain. 

Utilizing an extremely low-dose radiation amounting to just 0.8–5% of the dose used 

in brain metastasis treatment, HeLaXON releases radiation through carbon nanotubes. 

This allows precise adjustments to energy, angle, and dose, enabling customized treatment according 

to the patient's needs. The anti-inflammatory effects of low-dose radiation make it 

highly versatile, potentially treating conditions such as dementia, degenerative arthritis, 

Parkinson’s disease, and cognitive impairment in companion animals. 

Notably, this non-drug therapy is free of side effects and can reduce treatment costs per patient by 60–70%.

We hope this detailed look at HeLaXON 1X has been helpful!